MDI-0151 will be analysed to treat refractory inflammatory ailments caused by increased neutrophil activation. Credit: Mongkolchon Akesin / Shutterstock.

Melodia Therapeutics has signed an exclusive licence agreement to obtain the global development, manufacturing and commercialisation rights for Alivexis’ MDI-0151, a cathepsin C inhibitor.

The clinical candidate, stemming from Alivexis’ MOD-A discovery programme, is poised for investigational new drug application (IND)-enabling activities.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This will aid the commencement of Phase I/Phase IIa trials of the asset for refractory inflammatory ailments caused by increased neutrophil activation, such as ANCA-associated vasculitis.

The collaboration between Alivexis and Melodia will utilise their capabilities in drug discovery research and development to achieve clinical proof of concept for MDI-0151 in diseases linked to neutrophils.

Alivexis is entitled to receive an upfront payment from Melodia, with additional development and sales milestone payments up to Y42.7bn ($275m).

See Also:

Alivexis will also receive royalty payments on net product sales that reach the market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is eligible for warrants to subscribe for shares in Melodia.

Alivexis CEO S Roy Kimura stated: “This event marks a significant milestone for Alivexis and serves as validation of our drug discovery research and development team and platform, our proprietary pipeline of discovery programmes, and our business model involving the use of our cutting-edge platform to accelerate clinical candidate discovery for diseases with high unmet need.

“This is the first of many licensing and collaboration agreements that we anticipate from our maturing portfolio of IND-ready candidate molecules in our pipeline and our unique and proven discovery platform.

“We are confident that the Melodia team will be able to take our candidate molecule through clinical trials and ultimately help many patients in need suffering from chronic inflammatory diseases.”